Your browser doesn't support javascript.
loading
Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.
Bouvin-Pley, M; Morgand, M; Meyer, L; Goujard, C; Moreau, A; Mouquet, H; Nussenzweig, M; Pace, C; Ho, D; Bjorkman, P J; Baty, D; Chames, P; Pancera, M; Kwong, P D; Poignard, P; Barin, F; Braibant, M.
Afiliación
  • Bouvin-Pley M; Université François Rabelais, Inserm U966, Tours, France.
  • Morgand M; Université François Rabelais, Inserm U966, Tours, France.
  • Meyer L; Université Paris Sud, CESP Inserm U1018, Paris, France AP-HP Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.
  • Goujard C; Université Paris Sud, CESP Inserm U1018, Paris, France AP-HP Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.
  • Moreau A; Université François Rabelais, Inserm U966, Tours, France.
  • Mouquet H; Laboratory of Humoral Response to Pathogens, Department of Immunology, Institut Pasteur, Paris, France.
  • Nussenzweig M; Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA.
  • Pace C; Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York, USA.
  • Ho D; Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York, USA.
  • Bjorkman PJ; California Institute of Technology, Pasadena, California, USA.
  • Baty D; CRCM, Inserm U1068, Institut Paoli-Calmettes, CNRS UMR7258, Marseille, France.
  • Chames P; CRCM, Inserm U1068, Institut Paoli-Calmettes, CNRS UMR7258, Marseille, France.
  • Pancera M; Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
  • Kwong PD; Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
  • Poignard P; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA International AIDS Vaccine Initiative Neutralizing Antibody Center, La Jolla, California, USA.
  • Barin F; Université François Rabelais, Inserm U966, Tours, France Laboratoire de Bactériologie-Virologie and Centre National de Reference du VIH, CHU Bretonneau, Tours, France.
  • Braibant M; Université François Rabelais, Inserm U966, Tours, France braibant@med.univ-tours.fr.
J Virol ; 88(23): 13910-7, 2014 Dec.
Article en En | MEDLINE | ID: mdl-25231299
Extending our previous analyses to the most recently described monoclonal broadly neutralizing antibodies (bNAbs), we confirmed a drift of HIV-1 clade B variants over 2 decades toward higher resistance to bNAbs targeting almost all the identified gp120-neutralizing epitopes. In contrast, the sensitivity to bNAbs targeting the gp41 membrane-proximal external region remained stable, suggesting a selective pressure on gp120 preferentially. Despite this evolution, selected combinations of bNAbs remain capable of neutralizing efficiently most of the circulating variants.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Proteína gp120 de Envoltorio del VIH / Infecciones por VIH / VIH-1 / Flujo Genético / Anticuerpos Neutralizantes / Anticuerpos Monoclonales Límite: Animals / Humans / Male Idioma: En Revista: J Virol Año: 2014 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Proteína gp120 de Envoltorio del VIH / Infecciones por VIH / VIH-1 / Flujo Genético / Anticuerpos Neutralizantes / Anticuerpos Monoclonales Límite: Animals / Humans / Male Idioma: En Revista: J Virol Año: 2014 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos